JP2008504267A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008504267A5 JP2008504267A5 JP2007518190A JP2007518190A JP2008504267A5 JP 2008504267 A5 JP2008504267 A5 JP 2008504267A5 JP 2007518190 A JP2007518190 A JP 2007518190A JP 2007518190 A JP2007518190 A JP 2007518190A JP 2008504267 A5 JP2008504267 A5 JP 2008504267A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- indol
- alkyl
- sulfonyl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- -1 cycloheteroalkyl Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- IMZSLPYVKQTMKF-UHFFFAOYSA-N n-[2-[1-(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonylindol-3-yl]ethyl]acetamide Chemical compound C1=CC=C2C(CCNC(=O)C)=CN(S(=O)(=O)C=3N4C=CSC4=NC=3Cl)C2=C1 IMZSLPYVKQTMKF-UHFFFAOYSA-N 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- YXOMUADHSLTOIZ-UHFFFAOYSA-N 2-[1-(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonylindol-3-yl]acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CN(S(=O)(=O)C=3N4C=CSC4=NC=3Cl)C2=C1 YXOMUADHSLTOIZ-UHFFFAOYSA-N 0.000 claims 1
- 108091005435 5-HT6 receptors Proteins 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000003947 ethylamines Chemical class 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- ZSOAQDINSUCKGF-UHFFFAOYSA-N n-[[1-[(4-chloro-2-methylsulfanyl-1h-imidazol-5-yl)sulfonyl]indol-3-yl]methyl]acetamide Chemical compound N1C(SC)=NC(Cl)=C1S(=O)(=O)N1C2=CC=CC=C2C(CNC(C)=O)=C1 ZSOAQDINSUCKGF-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58229004P | 2004-06-23 | 2004-06-23 | |
| PCT/US2005/021852 WO2006002125A1 (en) | 2004-06-23 | 2005-06-21 | Indolylalkylamine metabolites as 5-hydroxytrytamine-6 ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008504267A JP2008504267A (ja) | 2008-02-14 |
| JP2008504267A5 true JP2008504267A5 (enExample) | 2008-07-24 |
Family
ID=35033547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007518190A Withdrawn JP2008504267A (ja) | 2004-06-23 | 2005-06-21 | ５−ヒドロキシトリプタミン−６配位子としてのインドリルアルキルアミン代謝物 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7498327B2 (enExample) |
| EP (1) | EP1758898A1 (enExample) |
| JP (1) | JP2008504267A (enExample) |
| KR (1) | KR20070041514A (enExample) |
| CN (1) | CN1976928A (enExample) |
| AR (1) | AR049449A1 (enExample) |
| AU (1) | AU2005258025A1 (enExample) |
| BR (1) | BRPI0512540A (enExample) |
| CA (1) | CA2570818A1 (enExample) |
| CR (1) | CR8825A (enExample) |
| EC (1) | ECSP067096A (enExample) |
| IL (1) | IL180198A0 (enExample) |
| MX (1) | MX2007000182A (enExample) |
| NO (1) | NO20070065L (enExample) |
| PA (1) | PA8637801A1 (enExample) |
| PE (1) | PE20060303A1 (enExample) |
| RU (1) | RU2006146923A (enExample) |
| TW (1) | TW200606148A (enExample) |
| WO (1) | WO2006002125A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9101613B2 (en) | 2006-02-15 | 2015-08-11 | Neurim Pharmaceuticals (1991) Ltd. | Methods for treating neurological disease |
| US7635710B2 (en) * | 2006-02-15 | 2009-12-22 | Neurim Pharmaceuticals (1991) Ltd. | Pyrone-indole derivatives and process for their preparation |
| EP1953153A1 (en) * | 2007-01-31 | 2008-08-06 | Laboratorios del Dr. Esteve S.A. | Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders |
| EP2053052A1 (en) | 2007-10-23 | 2009-04-29 | Laboratorios del Dr. Esteve S.A. | Process for the preparation of 6-substituted imidazo[2,1-b]thiazole-5-sulfonyl halide |
| EP3083588B1 (en) | 2013-12-20 | 2020-12-09 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic compounds and their application in pharmaceuticals |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3489767A (en) * | 1966-01-12 | 1970-01-13 | Sumitomo Chemical Co | 1-(phenylsulfonyl)-3-indolyl aliphatic acid derivatives |
| GB9820113D0 (en) * | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
| US6380166B1 (en) * | 1999-09-13 | 2002-04-30 | American Home Products Corporation | Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols |
| IL162243A0 (en) * | 2001-12-20 | 2005-11-20 | Wyeth Corp | Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
| WO2004078719A1 (ja) * | 2003-03-06 | 2004-09-16 | Ono Pharmaceutical Co., Ltd. | インドール誘導体化合物およびその化合物を有効成分とする薬剤 |
| WO2005009958A1 (en) * | 2003-07-17 | 2005-02-03 | Plexxikon, Inc. | Ppar active compounds |
| WO2005040112A1 (en) * | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds with pgd2 antagonist activity |
-
2005
- 2005-06-17 PE PE2005000696A patent/PE20060303A1/es not_active Application Discontinuation
- 2005-06-21 EP EP05766100A patent/EP1758898A1/en not_active Withdrawn
- 2005-06-21 CA CA002570818A patent/CA2570818A1/en not_active Abandoned
- 2005-06-21 TW TW094120536A patent/TW200606148A/zh unknown
- 2005-06-21 JP JP2007518190A patent/JP2008504267A/ja not_active Withdrawn
- 2005-06-21 AR ARP050102544A patent/AR049449A1/es unknown
- 2005-06-21 CN CNA2005800206836A patent/CN1976928A/zh active Pending
- 2005-06-21 BR BRPI0512540-5A patent/BRPI0512540A/pt not_active IP Right Cessation
- 2005-06-21 KR KR1020077000822A patent/KR20070041514A/ko not_active Withdrawn
- 2005-06-21 RU RU2006146923/04A patent/RU2006146923A/ru not_active Application Discontinuation
- 2005-06-21 WO PCT/US2005/021852 patent/WO2006002125A1/en not_active Ceased
- 2005-06-21 AU AU2005258025A patent/AU2005258025A1/en not_active Abandoned
- 2005-06-21 MX MX2007000182A patent/MX2007000182A/es active IP Right Grant
- 2005-06-22 US US11/158,702 patent/US7498327B2/en not_active Expired - Fee Related
- 2005-06-23 PA PA20058637801A patent/PA8637801A1/es unknown
-
2006
- 2006-12-19 EC EC2006007096A patent/ECSP067096A/es unknown
- 2006-12-19 IL IL180198A patent/IL180198A0/en unknown
- 2006-12-21 CR CR8825A patent/CR8825A/es not_active Application Discontinuation
-
2007
- 2007-01-04 NO NO20070065A patent/NO20070065L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6580760B2 (ja) | ブルトン型チロシンキナーゼ（Ｂｔｋ）の阻害剤の使用 | |
| ES2918548T3 (es) | Uso de 5-amino-2,3-dihidro-1,4-ftalazindiona en el tratamiento de esclerosis múltiple progresiva crónica | |
| JP7390415B2 (ja) | ニューロキニン－１受容体アンタゴニストとしての化合物およびその使用 | |
| JP6419072B2 (ja) | （ｓ）−３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンの塩及び固体形態、並びにそれらを含有する組成物及び使用方法 | |
| CN112074519A8 (zh) | 作为rip1激酶抑制剂用于治疗e.g.肠易激综合征（ibs）的n-[4-氧代-2,3-二氢-1,5-苯并氧氮杂䓬-3-基]-5,6-二氢-4h-吡咯并[1,2-b]吡唑-2-甲酰胺衍生物和有关化合物 | |
| CN114401952A (zh) | 作为整合应激通路的调节剂的被取代的环烷基化合物 | |
| JP5337054B2 (ja) | ムスカリン受容体アンタゴニストとベータ−２−アドレナリン受容体アゴニストの組み合わせ | |
| JP2018521017A5 (enExample) | ||
| CN101516192B (zh) | 5-氨基-3-(3'-脱氧-β-D-呋喃核糖基)-噻唑并[4,5-d]嘧啶-2,7-二酮的前药 | |
| AU2014240003B2 (en) | Coumarin derivatives and methods of use in treating hyperproliferative diseases | |
| ES2947293T3 (es) | Ligandos opioides kappa de heteroarilfenoxi benzamida | |
| CA2640223A1 (en) | Methods and compositions for treating schizophrenia | |
| RS52743B (sr) | (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciklo[2.2.2]okt-3-il)benzofuran-2-karboksamid, novi oblici soli i postupci za njihovu upotrebu | |
| JP2009538910A5 (enExample) | ||
| JP2019511575A (ja) | （Ｓ）−Ｎ−（５−（（Ｒ）−２−（２，５−ジフルオロフェニル）−ピロリジン−１−イル）−ピラゾロ［１，５−ａ］ピリミジン−３−イル）−３−ヒドロキシピロリジン−１−カルボキサミドの液体製剤 | |
| JP2009511508A5 (enExample) | ||
| JP2011506554A (ja) | Ｐ２ｘ７調節因子としての５−オキソ−３−ピロリジンカルボキサミド誘導体 | |
| CA2952111A1 (en) | Small molecule efflux pump inhibitors | |
| US20240197678A1 (en) | Inhibitors of the peptidyl-prolyl cis/trans isomerase (pin1) and uses thereof | |
| JP2008504267A5 (enExample) | ||
| JP5575663B2 (ja) | 置換された２−アミノ−３−（スルホニル）ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体アンタゴニスト、その調製のための方法及び使用 | |
| JP2008523146A5 (enExample) | ||
| RU2006146923A (ru) | Метаболиты индолилалкиламина в качестве лигандов 5-гидрокситриптамина-6 | |
| CN103827100B (zh) | 用于降低血清尿酸的[1,2,4]噻二嗪1,1-二氧化物化合物 | |
| JP7523146B2 (ja) | Ｈｄａｃ６阻害薬としての３－（２－（ヘテロアリール）－ピリジン－４－イル）－５－（トリフルオロメチル）－１，２，４－オキサジアゾール誘導体 |